Treatment  ||| S:0 E:10 ||| NN
effects  ||| S:10 E:18 ||| NNS
of  ||| S:18 E:21 ||| IN
intradermal  ||| S:21 E:33 ||| JJ
botulinum  ||| S:33 E:43 ||| JJ
toxin  ||| S:43 E:49 ||| NN
type  ||| S:49 E:54 ||| NN
A  ||| S:54 E:56 ||| DT
injection  ||| S:56 E:66 ||| NN
on  ||| S:66 E:69 ||| IN
alopecia  ||| S:69 E:78 ||| NNS
areata  ||| S:78 E:85 ||| VBP
There  ||| S:85 E:91 ||| EX
are  ||| S:91 E:95 ||| VBP
several  ||| S:95 E:103 ||| JJ
different  ||| S:103 E:113 ||| JJ
treatment  ||| S:113 E:123 ||| NN
options  ||| S:123 E:131 ||| NNS
for  ||| S:131 E:135 ||| IN
alopecia  ||| S:135 E:144 ||| JJ
areata  ||| S:144 E:151 ||| NNS
( ||| S:151 E:152 ||| -LRB-
AA ||| S:152 E:154 ||| NN
) ||| S:154 E:155 ||| -RRB-
;  ||| S:155 E:157 ||| :
Botulinum  ||| S:157 E:167 ||| NNP
toxin  ||| S:167 E:173 ||| NN
type  ||| S:173 E:178 ||| NN
A  ||| S:178 E:180 ||| DT
( ||| S:180 E:181 ||| -LRB-
BTXA ||| S:181 E:185 ||| NNP
)  ||| S:185 E:187 ||| -RRB-
can  ||| S:187 E:191 ||| MD
induce  ||| S:191 E:198 ||| VB
changes  ||| S:198 E:206 ||| NNS
in  ||| S:206 E:209 ||| IN
neurotransmitter  ||| S:209 E:226 ||| JJ
levels ||| S:226 E:232 ||| NNS
,  ||| S:232 E:234 ||| ,
directly  ||| S:234 E:243 ||| RB
or  ||| S:243 E:246 ||| CC
via  ||| S:246 E:250 ||| IN
neuroimmunologic  ||| S:250 E:267 ||| JJ
mechanisms ||| S:267 E:277 ||| NNS
.  ||| S:277 E:279 ||| .
Therefore  ||| S:279 E:289 ||| RB
it  ||| S:289 E:292 ||| PRP
is  ||| S:292 E:295 ||| VBZ
thought  ||| S:295 E:303 ||| VBN
that  ||| S:303 E:308 ||| IN
BTXA  ||| S:308 E:313 ||| NNP
may  ||| S:313 E:317 ||| MD
influence  ||| S:317 E:327 ||| VB
cytokines  ||| S:327 E:337 ||| NNS
that  ||| S:337 E:342 ||| WDT
are  ||| S:342 E:346 ||| VBP
responsible  ||| S:346 E:358 ||| JJ
for  ||| S:358 E:362 ||| IN
hair  ||| S:362 E:367 ||| NN
growth  ||| S:367 E:374 ||| NN
arrest  ||| S:374 E:381 ||| NN
that  ||| S:381 E:386 ||| IN
characterizes  ||| S:386 E:400 ||| JJ
AA ||| S:400 E:402 ||| NN
.  ||| S:402 E:404 ||| .
To  ||| S:404 E:407 ||| TO
prospectively  ||| S:407 E:421 ||| RB
examine  ||| S:421 E:429 ||| VB
the  ||| S:429 E:433 ||| DT
safety  ||| S:433 E:440 ||| NN
and  ||| S:440 E:444 ||| CC
efficacy  ||| S:444 E:453 ||| NN
of  ||| S:453 E:456 ||| IN
BTXA  ||| S:456 E:461 ||| NNP
injections  ||| S:461 E:472 ||| NNS
for  ||| S:472 E:476 ||| IN
the  ||| S:476 E:480 ||| DT
treatment  ||| S:480 E:490 ||| NN
of  ||| S:490 E:493 ||| IN
patients  ||| S:493 E:502 ||| NNS
with  ||| S:502 E:507 ||| IN
AA  ||| S:507 E:510 ||| NN
of  ||| S:510 E:513 ||| IN
the  ||| S:513 E:517 ||| DT
scalp ||| S:517 E:522 ||| NN
.  ||| S:522 E:524 ||| .
Seven  ||| S:524 E:530 ||| CD
patients  ||| S:530 E:539 ||| NNS
with  ||| S:539 E:544 ||| IN
AA  ||| S:544 E:547 ||| NN
received  ||| S:547 E:556 ||| VBD
10  ||| S:556 E:559 ||| CD
U  ||| S:559 E:561 ||| NNP
of  ||| S:561 E:564 ||| IN
BTXA  ||| S:564 E:569 ||| NNP
intradermal  ||| S:569 E:581 ||| NN
injections  ||| S:581 E:592 ||| NNS
on  ||| S:592 E:595 ||| IN
each  ||| S:595 E:600 ||| DT
site  ||| S:600 E:605 ||| NN
three  ||| S:605 E:611 ||| CD
times ||| S:611 E:616 ||| NNS
.  ||| S:616 E:618 ||| .
Subjects  ||| S:618 E:627 ||| NNS
were  ||| S:627 E:632 ||| VBD
classified  ||| S:632 E:643 ||| VBN
according  ||| S:643 E:653 ||| VBG
to  ||| S:653 E:656 ||| TO
the  ||| S:656 E:660 ||| DT
extent  ||| S:660 E:667 ||| NN
of  ||| S:667 E:670 ||| IN
scalp  ||| S:670 E:676 ||| JJ
hair  ||| S:676 E:681 ||| NN
loss  ||| S:681 E:686 ||| NN
into  ||| S:686 E:691 ||| IN
Severity  ||| S:691 E:700 ||| NNP
of  ||| S:700 E:703 ||| IN
Alopecia  ||| S:703 E:712 ||| NNP
Tool  ||| S:712 E:717 ||| NNP
subclasses ||| S:717 E:727 ||| NN
.  ||| S:727 E:729 ||| .
Two  ||| S:729 E:733 ||| CD
patients  ||| S:733 E:742 ||| NNS
had  ||| S:742 E:746 ||| VBD
one  ||| S:746 E:750 ||| CD
patch  ||| S:750 E:756 ||| NN
of  ||| S:756 E:759 ||| IN
AA ||| S:759 E:761 ||| NN
;  ||| S:761 E:763 ||| :
the  ||| S:763 E:767 ||| DT
remaining  ||| S:767 E:777 ||| JJ
patients  ||| S:777 E:786 ||| NNS
had  ||| S:786 E:790 ||| VBD
total  ||| S:790 E:796 ||| JJ
or  ||| S:796 E:799 ||| CC
universal  ||| S:799 E:809 ||| JJ
type  ||| S:809 E:814 ||| NN
AA ||| S:814 E:816 ||| NN
.  ||| S:816 E:818 ||| .
One  ||| S:818 E:822 ||| CD
patient  ||| S:822 E:830 ||| NN
dropped  ||| S:830 E:838 ||| VBD
out  ||| S:838 E:842 ||| RP
of  ||| S:842 E:845 ||| IN
the  ||| S:845 E:849 ||| DT
study  ||| S:849 E:855 ||| NN
after  ||| S:855 E:861 ||| IN
experiencing  ||| S:861 E:874 ||| VBG
spontaneous  ||| S:874 E:886 ||| JJ
recovery  ||| S:886 E:895 ||| NN
from  ||| S:895 E:900 ||| IN
her  ||| S:900 E:904 ||| PRP$
AA ||| S:904 E:906 ||| NN
.  ||| S:906 E:908 ||| .
One  ||| S:908 E:912 ||| CD
patient  ||| S:912 E:920 ||| NN
reported  ||| S:920 E:929 ||| VBD
aggravation  ||| S:929 E:941 ||| VBN
of  ||| S:941 E:944 ||| IN
her  ||| S:944 E:948 ||| PRP$
AA  ||| S:948 E:951 ||| NN
after  ||| S:951 E:957 ||| IN
BTXA  ||| S:957 E:962 ||| NNP
injections ||| S:962 E:972 ||| NNS
.  ||| S:972 E:974 ||| .
The  ||| S:974 E:978 ||| DT
remaining  ||| S:978 E:988 ||| JJ
patients ||| S:988 E:996 ||| NNS
'  ||| S:996 E:998 ||| POS
AA  ||| S:998 E:1001 ||| NN
did  ||| S:1001 E:1005 ||| VBD
not  ||| S:1005 E:1009 ||| RB
change  ||| S:1009 E:1016 ||| VB
after  ||| S:1016 E:1022 ||| IN
BTXA  ||| S:1022 E:1027 ||| NNP
injections ||| S:1027 E:1037 ||| NNS
.  ||| S:1037 E:1039 ||| .
Our  ||| S:1039 E:1043 ||| PRP$
results  ||| S:1043 E:1051 ||| NNS
suggest  ||| S:1051 E:1059 ||| VBP
that  ||| S:1059 E:1064 ||| IN
BTXA  ||| S:1064 E:1069 ||| NNP
injection  ||| S:1069 E:1079 ||| NN
cannot  ||| S:1079 E:1086 ||| RB
be  ||| S:1086 E:1089 ||| VB
used  ||| S:1089 E:1094 ||| VBN
as  ||| S:1094 E:1097 ||| IN
an  ||| S:1097 E:1100 ||| DT
alternative  ||| S:1100 E:1112 ||| JJ
treatment  ||| S:1112 E:1122 ||| NN
for  ||| S:1122 E:1126 ||| IN
recalcitrant  ||| S:1126 E:1139 ||| JJ
AA ||| S:1139 E:1141 ||| NN
.  ||| S:1141 E:1143 ||| .
Nevertheless ||| S:1143 E:1155 ||| RB
,  ||| S:1155 E:1157 ||| ,
future  ||| S:1157 E:1164 ||| JJ
studies  ||| S:1164 E:1172 ||| NNS
concerning  ||| S:1172 E:1183 ||| VBG
the  ||| S:1183 E:1187 ||| DT
treatment  ||| S:1187 E:1197 ||| NN
efficacy  ||| S:1197 E:1206 ||| NN
of  ||| S:1206 E:1209 ||| IN
BTXA  ||| S:1209 E:1214 ||| NNP
for  ||| S:1214 E:1218 ||| IN
mild  ||| S:1218 E:1223 ||| JJ
to  ||| S:1223 E:1226 ||| TO
moderate  ||| S:1226 E:1235 ||| JJ
AA  ||| S:1235 E:1238 ||| NN
are  ||| S:1238 E:1242 ||| VBP
warranted ||| S:1242 E:1251 ||| VBN
.  ||| S:1251 E:1253 ||| .
